H-Index
17
Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSMbanner

Annals
ISI-Home

Get your full text copy in PDF

Autoimmune Myelofibrosis in Sjögren’s Syndrome: Report of a Case

Seiji Kakiuchi, Ikumi Takagi, Hiroaki Akiyama, Hiroyuki Matsuba, Junpei Rikitake, Kazuyoshi Kajimoto, Yoshitake Hayashi, Nobuko Iwata

(Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan)

Am J Case Rep 2020; 21:e924983

DOI: 10.12659/AJCR.924983


BACKGROUND: Autoimmune myelofibrosis (AMF) is a rare clinicopathologic entity of bone marrow fibrosis that occurs in association with autoimmune disorders. Steroids are very effective for treatment of AMF and the disease has a good prognosis and should be distinguished from primary myelofibrosis.
CASE REPORT: A 49-year-old man with bleeding and petechial hemorrhage of the extremities presented to our institution. His platelet count was 1×10⁹/L. Bone marrow aspiration revealed a dry tap, and bone marrow biopsy confirmed small lymphocyte infiltration and increased reticular fibers, consistent with immune thrombocytopenia. Testing for mutations in JAK2, MPL, and CALR was negative. Because the patient had a history of Raynaud’s phenomenon, he was suspected to have collagen disease. Anti-Sjögren’s-syndrome-related antigen-A antibody testing, Schirmer’s test, and fluorescein staining all came back positive, which led to a diagnosis of Sjögren’s syndrome. Given the bone marrow findings, the patient also was diagnosed with AMF. Treatment with steroids resulted in an immediate improvement in his platelet count.
CONCLUSIONS: In the present case, treatment with steroids resulted in prompt improvement in platelet counts and subsequent marrow biopsy showed MF-0 reticulin fibrosis. Bone marrow fibrosis rarely is seen in association with autoimmune disease, and its significance and mechanism are still to be determined.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree